8:49 AM
 | 
Apr 05, 2018
 |  BC Extra  |  Financial News

RA Capital leads Eidos' $64M series B round

Eidos Therapeutics Inc. (San Francisco, Calif.) raised a $64 million series B round led by new investor RA Capital. Eidos' parent company, BridgeBio Pharma LLC (Palo Alto, Calif.), also participated, as did new investors...

Read the full 147 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >